Wave Life Sciences Q4 revenue beats analyst expectations

Reuters02-26
<a href="https://laohu8.com/S/WVE">Wave Life</a> Sciences Q4 revenue beats analyst expectations

Overview

  • Biotechnology firm's Q4 revenue beat analyst expectations

  • Net income and income from operations missed analyst estimates

  • Company advancing RNA medicines pipeline with multiple clinical trials in 2026

Outlook

  • Wave plans to initiate Phase 2a trial for WVE-007 in 1H 2026

  • Company expects regulatory feedback on WVE-006 approval pathway mid-2026

  • Wave aims to file CTA for WVE-008 for liver disease in 2026

Result Drivers

  • OBESITY TREATMENT - WVE-007 showed promising interim results in fat loss comparable to GLP-1, with muscle preservation, supporting its potential as a transformative obesity treatment

  • AATD ADVANCEMENTS - WVE-006 achieved key treatment goals for AATD, with dynamic AAT production and favorable safety, advancing towards potential accelerated approval

  • LIVER DISEASE FOCUS - WVE-008 is advancing for PNPLA3 I148M liver disease, with preparations for a clinical trial application in 2026

Company press release: ID:nGNX33SHp7

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$17.24 mln

$16.30 mln (16 Analysts)

Q4 EPS

-$0.30

Q4 Net Income

Miss

-$53.18 mln

-$45.92 mln (15 Analysts)

Q4 Income from Operations

Miss

-$56.47 mln

-$48.53 mln (15 Analysts)

Q4 Pretax Profit

Miss

-$53.18 mln

-$45.67 mln (14 Analysts)

Q4 Operating Expenses

$73.71 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $32.50, about 123.5% above its February 25 closing price of $14.54

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment